Creative Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Creative Planning’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,000	Closed	-$128K	–	2473
2020 Q3	$128K	Buy	+1,000	New	+$276K	﹤0.01%	1790
2020 Q1	–	Sell	-800	Closed	-$63K	–	2095
2019 Q4	$63K	Buy	+800	New	+$162K	﹤0.01%	1801
2018 Q4	–	Sell	-500	Closed	-$50K	–	2118
2018 Q3	$50K	Buy	+500	New	+$89K	﹤0.01%	1878

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Creative Planning's VRTX Position: Q1 2026 in Review

Creative Planning increased its Vertex Pharmaceuticals (VRTX) stake by 9% in Q1 2026, buying an estimated $4.2M and bringing the position to 109,524 shares worth $48.9M. The position accounts for 0.03% of the portfolio, ranked #223.

Creative Planning first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Creative Planning held 109,524 shares of Vertex Pharmaceuticals worth $48.9M as of Q1 2026.
Creative Planning bought 9,011 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.2M.
Vertex Pharmaceuticals made up 0.03% of Creative Planning's portfolio in Q1 2026, its #223 holding.
Creative Planning first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.